MO
Therapeutic Areas
Amicus Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Galafold (migalastat) | Fabry disease (amenable mutations) | Approved |
| Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) | Late-onset Pompe disease | Approved |
| AT-GTX-501 | CLN6 Batten disease | Phase 1/2 |
| AT-GTX-502 | CLN3 Batten disease (Juvenile) | Preclinical |
| AT-GTX-503 | CLN1 Batten disease (Infantile) | Preclinical |
Leadership Team at Amicus Therapeutics
JF
John F. Crowley
Executive Chairman & Former CEO
BL
Bradley L. Campbell
President & Chief Executive Officer
ES
Ellen S. Rosenberg
Chief Financial Officer
DQ
Daphne Quimi
Chief Operating Officer
JC
Jeffrey Castelli
Chief Portfolio Officer & Interim Chief Development Officer
GA
Gustavo A. Pesquin
Chief Commercial Officer
CB
Cedric B. Francois
Co-Founder & Former Chief Executive Officer
HD
Hung Do
Senior Vice President, Head of Gene Therapy
MD
Michael D. Raab
Former President & Chief Executive Officer
DM
David M. Stack
Board Member